ArticleJournal of gastrointestinal cancer2026
Prognostic Value of the Nutritional Risk Index and Hemoglobin-to-Platelet Ratio Score for Predicting Recurrence and Survival in Siewert II/III Gastroesophageal Junction Adenocarcinoma.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundPostoperative recurrence remains common in patients with Siewert type II/III gastroesophageal junction adenocarcinoma (AEG), and conventional TNM staging provides limited individualized prognostic information. This study aimed to develop and validate a composite Nutritional Risk Index and Hemoglobin-to-Platelet Ratio (NRI-HPR) score for predicting recurrence and survival.
methodsA total of 270 patients who underwent curative gastrectomy between 2011 and 2015 were included as the training cohort, and 117 patients treated between 2020 and 2023 were enrolled as an independent validation cohort. Patients were stratified into three NRI-HPR score groups according to predefined cutoffs. Survival outcomes and recurrence patterns were analyzed using Kaplan–Meier and Cox regression analyses. Prognostic nomograms incorporating NRI-HPR were constructed and validated.
resultsIn the training cohort, 5-year recurrence-free survival (RFS) rates were 79.6%, 60.3%, and 37.4% for NRI-HPR scores 0, 1, and 2, respectively (P < 0.001). Patients with score 2 exhibited a significantly higher recurrence rate than those with scores 0–1 (69.8% vs. 31.3%, P < 0.05), particularly for locoregional recurrence and distant metastasis. The NRI-HPR score also significantly stratified RFS and overall survival (OS) in the validation cohort (both P < 0.001). Nomograms incorporating NRI-HPR demonstrated superior predictive performance compared with TNM staging alone for both RFS and OS, with good calibration.
conclusionsThe NRI-HPR score is a practical biomarker for predicting recurrence and survival in Siewert II/III AEG and improves prognostic stratification beyond conventional staging.
Indexed as
Identifiers
42010005What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.